|Articles|September 1, 1998

Clinical and Economic Considerations of Epilepsy and Its Medical Management
Volume 4
Issue 9 Suppl

Vagus Nerve Stimulation

Author(s)Gershon Ney, MD

Download PDF: Vagus Nerve Stimulation

Articles in this issue

almost 28 years ago

Article

Participating Faculty

almost 28 years ago

Article

Medical Management of Epilepsy: Issues and Implications

almost 28 years ago

Article

Demographics and Cost of Epilepsy

almost 28 years ago

Article

Anticonvulsants: Choices and Costs

almost 28 years ago

Article

Care of Children With Epilepsy

almost 28 years ago

Article

Referral Centers and Specialized Care

almost 28 years ago

Article

Determining Costs and Cost-Effectiveness of Epilepsy

almost 28 years ago

Article

Selected Abstracts

almost 28 years ago

Article

CME Quiz

almost 28 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Vagus Nerve Stimulation

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Obesity, Insulin Resistance, and the Silent Progression of MASH: A Hepatologist's Perspective

Fifth Death Confirmed in NYC Legionnaires' Outbreak

Pirtobrutinib Plus Venetoclax-Rituximab Cuts CLL Progression 45%

How Portable Oxygen Is Changing Home Respiratory Care: Doug Francis